ES2137137B1 - Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica. - Google Patents

Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.

Info

Publication number
ES2137137B1
ES2137137B1 ES009801078A ES9801078A ES2137137B1 ES 2137137 B1 ES2137137 B1 ES 2137137B1 ES 009801078 A ES009801078 A ES 009801078A ES 9801078 A ES9801078 A ES 9801078A ES 2137137 B1 ES2137137 B1 ES 2137137B1
Authority
ES
Spain
Prior art keywords
obtaining
gabapentine
procedure
gabapentin
unhydrated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009801078A
Other languages
English (en)
Other versions
ES2137137A1 (es
Inventor
Llado Jordi Bosch
Cruz Rafael Garcia
Grau Elias Molins
Miguel M Carmen Conrubia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medichem SA
Original Assignee
Medichem SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES009801078A priority Critical patent/ES2137137B1/es
Application filed by Medichem SA filed Critical Medichem SA
Priority to EP99919275A priority patent/EP1083164B1/en
Priority to HU0102104A priority patent/HUP0102104A3/hu
Priority to AU37106/99A priority patent/AU3710699A/en
Priority to DE69912773T priority patent/DE69912773T2/de
Priority to IL13981799A priority patent/IL139817A/xx
Priority to PCT/ES1999/000127 priority patent/WO1999061408A1/es
Priority to US09/700,939 priority patent/US6521787B1/en
Priority to CA002333408A priority patent/CA2333408A1/en
Publication of ES2137137A1 publication Critical patent/ES2137137A1/es
Application granted granted Critical
Publication of ES2137137B1 publication Critical patent/ES2137137B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtención y su utilización para la obtención de gabapentina de calidad farmacéutica; se describe un nuevo polimorfo de gabapentina no hidratada, obtenido mediante la desecación por atomización o turbo-secado de una disolución acuosa de gabapentina, y su utilización para obtener gabapentina apta para su uso farmacéutico mediante un procedimiento consistente en someter dicho nuevo polimorfo a un proceso de cristalización en disolventes.
ES009801078A 1998-05-25 1998-05-25 Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica. Expired - Fee Related ES2137137B1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES009801078A ES2137137B1 (es) 1998-05-25 1998-05-25 Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
HU0102104A HUP0102104A3 (en) 1998-05-25 1999-05-10 Non-hydrated gabapentine polymorph, production process and utilization for producing pharmaceutical grade gabapentine
AU37106/99A AU3710699A (en) 1998-05-25 1999-05-10 Non-hydrated gabapentine polymorph, production process and utilization for producing pharmaceutical grade gabapentine
DE69912773T DE69912773T2 (de) 1998-05-25 1999-05-10 Nicht hydratisiertes gabapentin polymorph, herstellungsprozess und verwendung zur herstellung von gabapentin pharmazeutischer reinheit.
EP99919275A EP1083164B1 (en) 1998-05-25 1999-05-10 Non-hydrated gabapentin polymorph, production process and utilization for producing pharmaceutical grade gabapentin
IL13981799A IL139817A (en) 1998-05-25 1999-05-10 Non-hydrated gabapentin polymorpha process for thepreparation thereof and the use thereof for the p reparation of pharmaceutical grade gabapentin
PCT/ES1999/000127 WO1999061408A1 (es) 1998-05-25 1999-05-10 Polimorfo de gabapentina no hidratada, procedimiento para su obtención y su utilización para la obtención de gabapentina de calidad farmacéutica
US09/700,939 US6521787B1 (en) 1998-05-25 1999-05-10 Non-hydrated gabapentine polymorph, production process and utilization for producing pharmaceutical grade gabapentine
CA002333408A CA2333408A1 (en) 1998-05-25 1999-05-10 Non-hydrated gabapentin polymorph, a process for the preparation thereof and the use therefor for the preparation of pharmaceutical grade gabapentin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801078A ES2137137B1 (es) 1998-05-25 1998-05-25 Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.

Publications (2)

Publication Number Publication Date
ES2137137A1 ES2137137A1 (es) 1999-12-01
ES2137137B1 true ES2137137B1 (es) 2000-08-16

Family

ID=8303893

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009801078A Expired - Fee Related ES2137137B1 (es) 1998-05-25 1998-05-25 Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.

Country Status (9)

Country Link
US (1) US6521787B1 (es)
EP (1) EP1083164B1 (es)
AU (1) AU3710699A (es)
CA (1) CA2333408A1 (es)
DE (1) DE69912773T2 (es)
ES (1) ES2137137B1 (es)
HU (1) HUP0102104A3 (es)
IL (1) IL139817A (es)
WO (1) WO1999061408A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061188A1 (en) 1999-04-09 2000-10-19 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
ES2164527B1 (es) * 1999-04-26 2003-04-01 Medichen S A Procedimiento de obtencion de gabapentina de calidad farmaceutica.
SI1423168T1 (sl) 2001-09-03 2006-06-30 Newron Pharm Spa Farmacevtski sestavek, ki vsebuje gabapentin ali njegov analog in alfa-aminoamid, in njegova analgetska uporaba
US6800782B2 (en) 2001-10-09 2004-10-05 Warner-Lambert Co. Anhydrous crystalline forms of gabapentin
ITMI20022071A1 (it) * 2002-10-01 2004-04-02 Erregierre Spa Processo di sintesi dell'acido 1-(aminometil)cicloesanacetico cloridato.
US7417036B2 (en) 2002-11-12 2008-08-26 Tianjin Kinsly Pharmaceutical Co. Ltd. Crystal form of adefovir dipivoxil and its preparation
WO2004106281A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Crystalline gabapentin
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
US20110224435A1 (en) * 2007-08-07 2011-09-15 Ranbaxy Laboratories Limited Process for preparation of amorphous lopinavir
US20100222584A1 (en) * 2009-02-06 2010-09-02 Bach Pharma, Inc. Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them
PT2858989T (pt) 2012-05-17 2020-06-25 Genentech Inc Forma amorfa de um composto de pirimidinil-ciclopentano inibidor de akt, composições e métodos das mesmas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
US4894476A (en) 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii

Also Published As

Publication number Publication date
US6521787B1 (en) 2003-02-18
DE69912773T2 (de) 2004-09-30
HUP0102104A2 (hu) 2001-11-28
CA2333408A1 (en) 1999-12-02
EP1083164A1 (en) 2001-03-14
EP1083164B1 (en) 2003-11-12
IL139817A (en) 2005-11-20
WO1999061408A1 (es) 1999-12-02
IL139817A0 (en) 2002-02-10
HUP0102104A3 (en) 2002-11-28
DE69912773D1 (de) 2003-12-18
ES2137137A1 (es) 1999-12-01
AU3710699A (en) 1999-12-13

Similar Documents

Publication Publication Date Title
ES2137137B1 (es) Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
PE84799A1 (es) Metodos mejorados para el procesamiento de proteina c activada
DK0743860T3 (da) Fremstilling af hule mikrokapsler
SE0100901D0 (sv) New composition
FR2627696B1 (fr) Nouvelle forme galenique du fenofibrate
EA200300999A1 (ru) Хронотерапевтические дозированные формы
ES2190289T3 (es) Un procedimiento para esterilizar un dispositivo sanitario que posee un revestimiento hidrofilo.
PE1898A1 (es) Acido cristalino [r-(r ,r )]-2-(4-fluorofenil)-�-�-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino) carbonil]-1h-pirrol-1-heptanoico sal de calcio(2:1)
GT200500257AA (es) Procedimiento para producir derivados de amina opticamente activos
ES2153498T3 (es) Proceso para preparar formas de dosificacion farmaceutica solidas.
DK1133284T3 (da) Fremgangsmåde til fremstilling af krystallinske partikler
NO985821D0 (no) Substituerte cyklopentanforbindelser som er nyttige som neuramidaseinhibitorer
ATE353341T1 (de) Lösungsverzögerte celluloseether und ein verfahren zu ihrer herstellung
EA200300450A1 (ru) Фармацевтические растворы соединений модафинила
BR0011903A (pt) Composição antiviral; produto de papel fino; e processo para a fabricação de um produto de papel fino
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
ES2017098B3 (es) Procedimiento para la preparacion de una disolucion farmaceutica acuosa de un principio activo constituido por un acido organico.
KR880002541A (ko) α-인터페론의 적용 제형
TR27442A (tr) Sivi asindirici temizleme terkibi.
ES2164527B1 (es) Procedimiento de obtencion de gabapentina de calidad farmaceutica.
PE10595A1 (es) Metodo de elucion de antimonio a partir de fases solidas utilizando acido sulfurico concentrado con contenido de acido clorhidrico diluido
ES2163038T3 (es) Procedimiento para la preparacion de clavulanato de potasio.
DK0633924T3 (da) Anvendelse af rengøringsmidler til hårde overflader, især glas
HUP0004510A1 (hu) Eljárás L-dihidroorotsav előállítására és a vegyület alkalmazása
YU48218B (sh) Derivati karbamoila

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19991201

Kind code of ref document: A1

Effective date: 19991201

FD1A Patent lapsed

Effective date: 20101018